Clinical Trial: [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07020806) titled '[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)' on May 21.

Brief Summary: This is a prospective study using [68Ga]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Lobular Breast Carcinoma

Intervention: DRUG: [68Ga]Ga DOTA-5G

Patients will be injected with up to 5 mCi of [68Ga]Ga DOTA-5G and imaged at 1 and 2 hours post injection.

Recruitment Status: RECRUITING

Sponsor: University of California, Davis

Information provided by (...